Lv2
190 积分 2022-12-10 加入
Drug discovery targeting thyroid hormone receptor β (THRβ) for the treatment of liver diseases and other medical indications
5小时前
已完结
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
2个月前
已完结
Thyroid Hormones, Thyromimetics and Their Metabolites in the Treatment of Liver Disease
2个月前
已完结
Current therapies and new developments in NASH
2个月前
已完结
Research advances in the diagnosis and treatment of MASLD/MASH
2个月前
已完结
Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options
2个月前
已完结
Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD
2个月前
已完结
Combination therapy of TERN-501, a selective agonist of thyroid hormone receptor (THR) beta with TERN-101, a farnesoid X receptor (FXR) agonist improves non-alcoholic steatohepatitis (NASH) in a GAN diet-induced and biopsy-confirmed mouse model
2个月前
已完结
Thyroid hormone and the Liver
2个月前
已完结
New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024
2个月前
已完结
皖公网安备34019202002308
